Related by context. Frequent words. (Click for all words.) 72 Paragraph IV 69 Paragraph IV certification 65 Abbreviated New 63 Generic Version 61 FDA Accepts 61 Drug Application 61 Citizen Petition 59 Complete Response 58 Drug Application ANDA 58 FastMarkets Ltd 58 NYSE MYL 58 BioDelivery Sciences 58 Teva Pharmaceuticals USA 58 Company Nasdaq PRGO 57 Late Filing 56 USFDA approval 56 Synthon 56 Medicis Pharmaceutical Corporation 56 Extended Release 56 ANDAs 55 FDA approvable letter 55 Staff Determination Letter 55 Complete Response letter 55 NASDAQ Listing 55 Oscient Pharmaceuticals 55 ANDA 55 FDA Approval 54 Barr Laboratories Inc. 54 Lupin Ltd 54 USFDA 54 Par Pharmaceutical 54 Pendency 54 IMPAX Laboratories Inc. 54 Act PDUFA date 54 Presents Positive 54 Patent Infringement 54 Golar LNG Limited 54 Somaxon Pharmaceuticals 54 ANDA approvals 53 Permanent Injunction 53 NYSE BRL 53 Full Prescribing Information 53 Option Grants 53 Paladin Labs 53 FDA Clearance 53 Ranbaxy Laboratories Limited 53 pediatric exclusivity 53 FDA Clears 53 Penwest Pharmaceuticals Co. 53 Action Lawsuits 53 Opana ER 53 Patent Litigation 53 ISTA Pharmaceuticals Inc. 52 KV Pharmaceutical Company 52 SCHWARZ PHARMA 52 Staff Deficiency Letter 52 Securities andExchange Commission 52 Receives Positive 52 Warning Letter 52 Ltd. Nasdaq TEVA 52 Oscient 52 Q2 Loss Narrows 52 Staff Determination 52 Extends Tender Offer 52 Par Pharmaceuticals 52 Receives Notice 51 Generex Biotechnology 51 Aurobindo Pharma 51 Approvable Letter 51 ISTA Pharmaceuticals 51 Marketing Authorization 51 Prescribing Information 51 Phase III Clinical Trial 51 GlaxoSmithKline plc GSK 51 binding Letter 51 Completes Enrollment 51 IPXL 51 Positive Opinion 51 Patient Enrollment 51 Clinical Trial Results 51 Glenmark Generics 51 Stalevo 51 Ondansetron 51 DepoMed 51 Drug Candidate 51 Intellipharmaceutics 51 FDA Orphan Drug 51 Pennsaid R 51 Sun Pharmaceutical Industries 51 Vitaros 51 Exclusive License 51 Roxane Laboratories 50 Duramed Pharmaceuticals Inc. 50 Palatin Technologies Inc. 50 Extended Release Tablets 50 Biotie 50 Counterclaim 50 Q2 Loss Widens 50 BioSante Pharmaceuticals 50 Q4 Loss Widens 50 Final Approval